French companies announced €30.4bn investments in 2025, including €9.2bn in new projects. Healthcare sits at the core of this momentum, strengthening industrial capacity, R&D and health sovereignty. Spread across 151 projects, these commitments prioritize healthcare, AI and green industry to deliver sustainable competitiveness.
Key figures for 2025
- €30.4bn invested over twelve months, 151 projects.
- €9.2bn in new commitments announced in November.
- Strategic sectors: healthcare, AI/digital, green industry, chemicals, agri-food, space.
Why healthcare matters for B2B
Industrialization & time-to-market
Plant extensions and modular sites reduce qualification timelines, increase throughput and secure quality.
AI & regulatory compliance
Investments in digital infrastructure and clinical AI enable smart manufacturing, traceability and compliance support.
Supply chain resilience
Relocating in France lowers logistics exposure and strengthens health sovereignty for medicines and medical devices.
Use case — URGO
Urgo is building a new 4.0 plant in Andrézieux-Bouthéon (Loire): 35,000 m², €60 M by 2029 and ~200 direct jobs (plus ~115 indirect over ten years). The site will integrate production and logistics to master medical compression (UrgoK2) 100% made in France, with workforce upskilling via its internal Textile School.
Pharma spotlight
Sanofi: Sanofi is committing €700 M in 2025-2026 to modernize French sites, plus €300 M for AI-dedicated equipment. Added to €2.5bn annual R&D, the strategy builds on mRNA platforms and bioproduction reinforcements.
France’s HealthTech ecosystem
France counts over 2,600 health companies and 75,000 direct jobs. Health industries generated €90bn in revenue (35% exported) and digital health fundraising reached €1.8bn in 2023, underscoring international attractiveness.
B2B opportunities
French and international companies benefit from a high-performing industrial environment in France, enabling them to accelerate the market launch of their innovations. For example, GSK is investing €160 million to modernize its sites and integrate new vaccine technologies, while Kenvue (formerly Johnson & Johnson) is dedicating €39 million to the production of innovative treatments in Val-de-Reuil. Norgine, meanwhile, is expanding its capacity in Dreux to support exports and create new jobs.
Integrating artificial intelligence and data into industrial processes offers a dual advantage: ensuring compliance with international standards and optimizing smart manufacturing. Several players, such as Sanofi and French Tech start-ups, are already leveraging these technologies to strengthen their competitiveness and accelerate the sector’s digital transformation.
Finally, relocating production sites to France and connecting them to global networks enhances supply chain resilience. Groups like Mayoly and Urgo exemplify this strategy by bringing strategic production back to France and creating new jobs locally.
